AGIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AGIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Agios Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was $-1.61.
During the past 3 years, the average EBITDA Per Share Growth Rate was -13.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -5.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Agios Pharmaceuticals was 11.20% per year. The lowest was -62.70% per year. And the median was -18.85% per year.
For the Biotechnology subindustry, Agios Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Agios Pharmaceuticals (NAS:AGIO) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of Agios Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Goff | director, officer: Chief Executive Officer | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
Sarah Gheuens | officer: Chief Medical Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
James William Burns | officer: Chief Legal Officer | C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Jacqualyn A Fouse | director | C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108 |
Tsveta Milanova | officer: Chief Commercial Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139 |
Cecilia Jones | officer: Chief Financial Officer | C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Kaye I Foster-cheek | director | JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
Washburn Theodore James Jr. | officer: Principal Accounting Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Jeffrey D Capello | director | C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912 |
Catherine E. Owen | director | 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067 |
David P Schenkein | director, 10 percent owner, officer: Chief Executive Officer | C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Cynthia Smith | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Rahul D. Ballal | director | 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116 |
Richa Poddar | officer: Chief Commercial Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Carman Alenson | officer: Principal Accounting Officer | 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 12-12-2022
By GuruFocus Research • 01-12-2024
By sperokesalga sperokesalga • 04-19-2023
By sperokesalga sperokesalga • 05-04-2023
By sperokesalga sperokesalga • 05-11-2023
By sperokesalga sperokesalga • 02-23-2023
By sperokesalga sperokesalga • 06-05-2023
By Stock market mentor Stock market mentor • 01-03-2023
By PRNewswire PRNewswire • 04-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.